Optimization of GPR40 Agonists for Type 2 Diabetes.
ACS Med Chem Lett
; 5(5): 517-21, 2014 May 08.
Article
en En
| MEDLINE
| ID: mdl-24900872
ABSTRACT
GPR40 (FFA1 and FFAR1) has gained significant interest as a target for the treatment of type 2 diabetes. TAK-875 (1), a GPR40 agonist, lowered hemoglobin A1c (HbA1c) and lowered both postprandial and fasting blood glucose levels in type 2 diabetic patients in phase II clinical trials. We optimized phenylpropanoic acid derivatives as GPR40 agonists and identified AMG 837 (2) as a clinical candidate. Here we report our efforts in searching for structurally distinct back-ups for AMG 837. These efforts led to the identification of more polar GPR40 agonists, such as AM-4668 (10), that have improved potency, excellent pharmacokinetic properties across species, and minimum central nervous system (CNS) penetration.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
ACS Med Chem Lett
Año:
2014
Tipo del documento:
Article
País de afiliación:
Estados Unidos